Wells Fargo raised the firm’s price target on Spyre Therapeutics (SYRE) to $90 from $50 and keeps an Overweight rating on the shares. With SPY001 showing significantly better efficacy at M3 than Entyvio’s historical data, the firm notes a highly differentiated monotherapy product profile has emerged, serving as a high launching point for combos and also providing strong downside protection.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics price target raised to $88 from $55 at Deutsche Bank
- Closing Bell Movers: Bloom Energy spikes on expanded Oracle deal
- Spyre Therapeutics announces $300M offering of common stock
- Spyre Therapeutics Pauses At-The-Market Equity Offering Program
- Spyre Therapeutics initiated with a Strong Buy at Raymond James